کارگاه‌های آموزشی مرکز اطلاعات علمی

مقاله نویسی علوم انسانی

اصول تنظیم قراردادها

آموزش مهارت های کاربردی در تدوین و چاپ مقاله
Burden of gastrointestinal cancer in Asia; an overview

Mohamad Amin Pourhoseingholi¹, Mohsen Vahedi², Ahmad Reza Baghestani³
¹Gastroenterology and Liver Diseases Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran
²Department of Epidemiology and Biostatistics, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
³Department of Biostatistics, Shahid Beheshti University of Medical Sciences, Tehran, Iran

ABSTRACT

The cancers in the digestive system including gastric cancer, colorectal cancer, liver cancer, esophageal cancer and pancreatic cancer are one of the most common cancers in Asia. The burden of GI cancer is increasing in Asia because of aging, growth of the population and the risk factors including smoking, obesity, changing lifestyle and high prevalence of H pylori, HBV and HCV. In most Asian countries, cancer control programs or early detection and treatment services are limited despite this increase. There are many people in the developing countries inside Asia who have no health insurance and many of them are too poor to go for screening tests, early detection or medical treatments. Therefore, it is important for the health organizations and governments in each country to recognize these groups and reduce the incidence and mortality of gastrointestinal cancers, using simple and economic screening test, vaccination and changing risk factors such as smoking, diet and lifestyle by education programs.

Keywords: Gastrointestinal cancers, Burden, Asia.

Introduction

Cancer is known as one of the major causes leading to many disorders, death, and disabilities worldwide (1). Among all organ cancers, gastrointestinal tract cancers (GI cancers) present an interesting pattern in distribution over the world. GI cancer is a term for the group of cancers that affect the digestive system, including gastric cancer (GC), colorectal cancer (CRC), hepatocellular carcinoma (HCC), esophageal cancer (EC) and pancreatic cancer (PC). Overall, the GI cancers are responsible for more cancers and more deaths from cancer than any other cancers. There is an increasing burden (incidence and mortality) in GI cancer worldwide and Asia is no exception (2).

Asia is the most populous continent in the world. Asia's population is raising faster than Europe or America and it covers approximately 4 billion people which hosts 60% of the world's current human population. According to information on the Lancet Asia Medical Forum website, the number of new cancer cases in Asia is set to increase from 3.5 million in 2002 to 8.1 million by 2020 if "current prevention and management strategies remain unchanged". The most common cancers in the digestive system including gastric cancer, colorectal cancer, liver cancer, esophageal cancer and pancreatic cancer are one of the most common cancers in Asia (3).

In this brief review, we discussed the burden of these common GI cancers in Asia according to...
recently published studies on mortality, incidence and epidemiology of these cancers in Asian countries. Besides, the age-standardized rate (ASR) of incidence for Asia in 2012 (according to GLOBOCAN estimation) was employed in order to compare it with western countries.

1. Gastric Cancer
Gastric cancer (GC) is an important cause of mortality due to cancer (4) and is estimated to be one of the most leading causes of all deaths worldwide (5).

Although the incidence of GC is decreasing, it is rarely detected early, and the prognosis remains poor. The majority of GC shows distant metastasis at the time of diagnosis (6). There is considerable variation in the incidence of GC among different geographic regions in the world. Nearly two-thirds of GC occurs in developing countries (7). The global age-standardized incidence in both men and women is concentrated primarily in Asia (8) and the highest incidence has been reported from some eastern Asian countries such as China, Korea and Japan (9). And regionally, gastric cancer is the first most common cancer in eastern Asia and the highest estimated mortality rates are in this region (8). In Iran, located in Middle East, it is the most frequently diagnosed form of cancer and its trend is increasing (10). Low incidence rates are found in south Asia (11).

The age-adjusted rates have been observed to be dramatically falling in all countries including China, Japan. However, the crude rates are estimated to rise substantially between the years 2000 to 2020 (12). Besides, it is predicted that the burden of GC has recently shown decreased incidence and mortality rate (13). The age-standardized rate (ASR) of incidence for Asia in 2012 according to GLOBOCAN estimation was 15.8 and ASR mortality was 11.7 per 100,000 (table 1). After East Asia, the incidence and mortality rate was higher in western Asia, but lower for south-central and southeastern regions of the continent (Figure 1) (14).

*Helicobacter pylori* (*H pylori*) is one of the GC’s risk factors and countries with high gastric cancer rates typically have a high prevalence of *H. pylori* infection, for instance, in Korea, 90% of asymptomatic adults over the age of 20 years are infected by *H. pylori* (15). On the other hand, the decline in *H. pylori* prevalence is in correspondence to decreasing incidence of GC (16). The incidence of GC is low in some parts of Indonesia (17, 18), which would be due to the infrequency of *H. pylori*. Similar results have been reported in Malaysia, (except for Chinese people in Penang) where the *H. pylori* infection rate is exceptionally low (19). Whether some dietary factor may be playing a role remains unclear.

2. Colorectal Cancer
Colorectal cancer is now the third most common malignant disease in Asia (20). In Eastern Asia, countries such as China, Japan, South Korea and Singapore have experienced an increasing incidence in the past decades and among ethnic groups in Asia, the incidence of colorectal cancer is significantly higher among the Chinese (20). A rapid increase in incidence of colorectal cancer has also been reported in Taiwan (21). In Middle East, the incidence of colorectal cancer is increasing (22, 23).

The mortality of CRC is higher in the less developed regions of the world, reflecting a poorer survival in these regions. Its mortality has been increasing in the last decade in Asian countries, except in Japan and Singapore (20). Other studies reported increasing trend of mortality due to CRC in Korea, China and Iran (24-27).
GLOBOCAN estimation project for 2012 indicated that, the ASR incidence for Asia was 13.7 and ASR mortality was 7.2 per 100,000 (table 1). Although the incidence and mortality rate of this cancer are still higher in western Asia, the ratio of mortality/incidence for Asian regions are higher, which means that the poor survival (figure 2) (14).

According to Asia Pacific cohort studies collaboration, smoking, body mass index and lack of physical activity increased risk of CRC (28).

Figure 1. The mortality and incidence of Gastric cancer in the world, according to GLOBOCAN estimation project, 2012.

![Figure 1](image1)

Figure 2. The mortality and incidence of colorectal cancer in the world, according to GLOBOCAN estimation project, 2012.

Screening can reduce the burden and mortality. In most Asian countries, national health-care systems and health insurance cover only a minority of
people (29) and there is little health authority support for colorectal cancer screening and very low public awareness of this emerging epidemic in Asia.

3. Hepatocellular Carcinoma:
The distribution of hepatocellular carcinoma (HCC) is heterogeneous with a high prevalence seen in Asia (30) and eighty percent of the burden is borne by countries in Asia and sub-Saharan Africa (31). The regions of high incidence and mortality are eastern and Southeastern Asia (Figure 3) and the highest liver cancer rate in the world is in Qidong, China, based on the cancer registry reporting and another high rate is also reported from Thailand (31). According to GLOBOCAN for 2012, the ASR incidence was 13.3 and ASR mortality was 12.6 per 100,000 (Table 1) (14).

HCV and HBV are the major etiological agents that lead to the development of HCC (32). The majority of infected people with HBV reside in the HCC high-risk regions of Asia and Africa. In the Asian eastern countries, HBV is the first cause of HCC. In India, HBV is the major risk factors, and Asian countries such as Hong Kong and Taiwan also had high incidence of HBV-related HCC (33). In Japan HBsAg-positive cases of HCC constituted 42% in 1977–1978, but recently reduced (34). In Korea approximately 65–75% of HCC patients are positive for HBsAg (35). In Iran, the most cause of HCC is HBV and 80% of HCC cases are positive for at least one of the markers of hepatitis B virus (36). Anti-HCV positives are significantly associated with the development of HCC, (25) and the co-infection of hepatitis B and C is associated with a further increased risk of HCC (30).

The other risk factor is aflatoxin (37), which is prevalent particularly in Africa, Southeast Asia and China (38) and most HCC cases due to aflatoxin occur in southeast Asia and China, where populations suffer from both high HBV prevalence and largely uncontrolled exposure to aflatoxin in the food. Alcohol as the other risk factor has important role in low incidence areas than in high incidence areas like Japan (39). The mortality is increasing in China (40, 41) decreasing in Korea and Japan (42, 43) and reaching a plateau in Iran (36).

4. Esophageal Cancer:
Esophageal cancer (EC) is one of the most common cancers worldwide (44). Survival rates are very low (45) and its prognosis is poor (46). The incidence and mortality rates show a wide geographical variation with differences between
high-and low-risk areas (9, 44). EC is a relatively rare form of cancer and around 80% of the cases worldwide occur in less developed regions but some areas have a higher incidence than others like China, Iran, India, Japan, and the region around the Caspian Sea (7). The eastern region and then south-central region have the high incidence and mortality, compared to other parts of continent (figure 4) (14).

Figure 4. The mortality and incidence of Esophageal cancer in the world, according to GLOBOCAN estimation project, 2012

The eastern part of the Caspian littoral area of Iran has the highest incidence of EC in the world (47).

In China EC is ranked second in incidence (48). However, recent study revealed that incidence and mortality rates for EC are decreasing due to changes in population, dietary patterns and food preservation methods (49). In Japan a decrease in mortality was observed as well (50). In Iran (which has a high incidence in its Caspian region) the mortality is increasing dramatically (51). According to GLOBOCAN project for Asia in 2012, the ASR incidence was 7.7 and ASR mortality was 6.7 per 100,000 (Table 1) (14).

5. Pancreatic Cancer:
Pancreatic cancer is a rapidly fatal cancer with the poorest survival rate of any major malignancy, only with 25-30% five-year survival after surgery and the mortality approaching the incidence (52). The mortality rates of pancreatic cancer in developed countries such as Australia and Japan ranged from 6 to 8 per 100,000 in males, and 4 to 6 in females (53). However, in these countries, the mortality rate of pancreatic cancer, have leveled off after an increase (54).

In some Asian countries, such as Korea and Singapore, the mortality are also high but, not reaching the peak yet (53) and in China the death rate due to pancreatic cancer was rising and the peak mortality might arrive in future (55). In Iran, trend of pancreatic cancer mortality was slightly decreased and is going to be leveled off in recent decade (56, 57). GLOBOCAN estimation for Asia in 2012 showed that ASR incidence was 3.2 and ASR mortality was 3.0 per 100,000 (table 1) (14).

Pancreatic cancer is one of the diseases that are correlated with industrialization and statistics suggested that majority of deaths occurred in developed countries (1). Smoking, type 2 diabetic mellitus and obesity are widely accepted as the risk factors for pancreatic cancer (58). On the other hand, we face the recent substantial increases in the prevalence of cigarette smoking; type 2 diabetic mellitus, and obesity in Asian countries and recent studies in Asia revealed that
smoking, obesity, and diabetes are important and potentially risk factors for pancreatic cancer in populations of the Asia-Pacific region (59, 60).

**Conclusion**

Asia’s burden of GI cancer is predicted to increase. Liver, gastric and esophageal cancers are relatively common in Asia. Three fourths of worldwide liver cancer cases in males and two thirds in females occur in the fifteen Asian countries and China alone has more than half of newly diagnosed liver cancer cases in the world. The prevalence of liver cancer is still high in Asia (30) and the main challenge is the high prevalence of chronic hepatitis (61). Although, HBV vaccination in these areas like China should be the major preventive tactic (31). Gastric cancer is the other GI cancer, rising in Asia. Although age-adjusted rate of GC is falling, the absolute number of cases and deaths are rising because of the increasing size and age of the world population, especially in the developing countries. Japanese experience revealed that, the availability of screening for early detection in high-risk areas has led to a decrease in mortality of this fatal cancer (62). The essential strategy for prevention and control the burden of GC in Asian countries with highest incidence would be focus on controlling *H. pylori* infection and improving educational levels, advocating healthy diet and also cost-effective early detection programs (63, 64).

Colorectal cancer is increasing in Asian population; the changing epidemiology is very worrying as the rising incidence in Asia (65). The increasing rate means that we need to take action immediately to prevent colorectal cancer and to diagnose the disease at the early stages by the cost-effectiveness of screening program (66). Esophageal cancer also occurs disproportionately in Asia, greater than 70% of new cases in males and females occur in the fifteen Asian countries. Low general awareness about the symptom of EC and delay in diagnosis of EC due to lack of a national comprehensive system for early detection of this cancer lead to diagnosis of EC in older ages and the subsequent higher mortality rates. Therefore, conducting a program to increase general awareness of known and probable risk factors of EC may be helpful to reduce EC incidence, especially in high incidence area.

Finally, the last but not the least GI cancer in Asia, is pancreatic cancer. However, the rate is not too high. Recent studies revealed that smoking, obesity, and diabetes are important and potentially risk factors, as similar as the western countries, for pancreatic cancer in populations of the Asia-Pacific region (76, 77). Thus, the activities to prevent them can be lead to reduction in the incidence and mortality of this cancer in Asian countries.

Whereas, the limitation of the incidence and mortality data due to incomplete registration sources for low income countries, the burden of GI cancer is increasing in Asia because of aging, growth of the population and the risk factors including smoking, obesity, changing lifestyle and high prevalence of *H. pylori*, HBV and HCV. On the other hand, there are many people in the developing countries inside Asia who have no health insurance and many of them are too poor to go for screening tests, early detection or medical treatments. Thus, it is important for the health organizations and governments in each country to recognize these groups and reduce the incidence and mortality of GI cancers, using simple and economic screening test, vaccination and changing risk factors such as smoking, diet and lifestyle by education programs.

**References**

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2014. [In press]
2. Sung J, Ng E, Lin JT, Ho K, Ji JF, Sugano K, et al; On behalf of the Asia Pacific GI Oncology Summit Group. Digestive Cancer Management in Asia: Position Statements- a report on GI Oncology Summit in 2011. J Gastroenterol Hepatol 2012; 27:1417-22.

3. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127:2893-917.

4. Samarasam I, Chandran BS, Sitaram V, Perakath B, Nair A, Mathew G. Palliative gastrectomy in advanced gastric cancer: is it worthwhile? ANZ J Surg 2006; 76:60-3.

5. Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380:2197-223.

6. Ozkan K, Turkkan E, Ender K, Mutlu D, Murat A, Nalan B, et al. 5-Fluorouracil, epirubicin and cisplatin in the treatment of metastatic gastric carcinoma: a retrospective analysis of 68 patients. Indian J Cancer 2005; 42:85-8.

7. Stewart BW, Kleihues P. World cancer report. Lyon: IARC Press; 2003.

8. Pourfarzi F, Whelan A, Kaldor J, Malekzadeh R. The role of diet and other environmental factors in the causation of gastric cancer in Iran—A population based study. Int J Cancer 2009; 125:1953-60.

9. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002: cancer incidence, mortality and prevalence worldwide, version 2.0. Lyon- France: IARC Press; 2004.

10. Mousavi SM, Somi MH. Gastric Cancer in Iran 1966-2006. Asian Pac J Cancer Prev 2009; 10:407-12.

11. Crew KD, Neugut AI. Epidemiology of gastric cancer. World J Gastroenterol 2006; 12:354-62.

12. Ferlay J, Bray F, Pisani P, Parkin DM. Globocan 2000: Cancer Incidence, Mortality, and Prevalence Worldwide. Version 1.0 IARC Cancer Base No. 5. Lyon: IARC Press; 2000.

13. Matsuzaka M, Fukuda S, Takahashi I, Shimaya S, Oyama T, Yaegaki M, et al. The decreased burden of Gastric Cancer in Japan. Tohoku J Exp Med 2007; 212:207-19.

14. GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012. Available from URL: http://globocan.iarc.fr/Default.aspx.

15. Youn HS, Ko GH, Chung MH, Lee WK, Cho MJ, Rhee KH. Pathogenesis and prevention of stomach cancer. J Korean Med Sci 1996; 11: 373-85.

16. Malfettheiner P, Selgrad M. Helicobacter pylori. Curr Opin Gastroenterol 2014; 30:589-95.

17. Tokudome S, Soeripto, Triningsih FX, Ananta I, Suzuki S, Kuriki K, et al. Rare Helicobacter pylori infection as a factor for the very low stomach cancer incidence in Yogyakarta, Indonesia. Cancer Lett 2005; 219:57-61.

18. Tokudome S, SamsuriaSoeripto WD, Triningsih FX, Suzuki S, Hosono A, Triono T, et al. Helicobacter pylori infection appears essential for stomach carcinogenesis - observations in Semarang, Indonesia. Cancer Sci 2005; 96: 873-75.

19. Gurjeet K, Subathra S, Bhupinder S. Differences in the pattern of gastric carcinoma between north-eastern and north-western peninsular Malaysia: a reflection of Helicobacter pylori prevalence. Med J Malaysia 2004; 59: 560-1.

20. Sung JJY, Lau JYW, Goh KL, Leung WK, for the on Asia Pacific Working Group on Colorectal Cancer. Increasing incidence of colorectal cancer in Asia: implications for screening. Lancet Oncol 2005; 6:871-6.

21. Yang L, Parkin DM, Li LD, Chen YD, Bray F. Estimation and projection of the national profile of cancer mortality in China: 1995 to 2005. Br J Cancer 2004; 90: 2157-66.

22. Moghimi-Dehkordi B, Safaee A, Zali MR. Prognostic factors in 1,138 Iranian colorectal cancer patients. Int J Colorectal Dis 2008; 23:683-8.

23. Azadeh S, Moghimi-Dehkordi B, Fatem SR, Pourhoseingholi MA, Ghiasi S, Zali MR. Colorectal cancer in Iran: an epidemiological study. Asian Pac J Cancer Prev 2008; 9:123-6.

24. Bae JM, Jung KW, Won YJ. Estimation of cancer death in Korea for the upcoming years. J Korean Med Sci 2002; 17: 611-15.

25. Yang L, Parkin DM, Li L, Chen Y. Time trends in cancer mortality in China: 1987–1999. Int J Cancer 2003; 106: 771-83.

26. Pourhoseingholi MA, Faghihzadeh S, Hajizadeh E, Abadi A, Zali MR. Bayesian estimation of colorectal cancer mortality in the presence of misclassification in Iran. Asian Pac J Cancer Prev 2009; 10:691-4.

27. Pourhoseingholi MA, Faghihzadeh S, Hajizadeh E, Gatta G, Zali MR, Abadi AR. Trend Analysis of Gastric Cancer and Colorectal Cancer Mortality in Iran, 1995-2003. Iran J Cancer Prev 2011; 1:38-43.
28. Huxley R; Asia Pacific Cohort Studies Collaboration. The role of lifestyle risk factors on mortality from colorectal cancer in populations of the Asia-Pacific region. Asian Pac J Cancer Prev 2007; 8:191-8.

29. Sung JJ, Lau JY, Goh KL, Leung WK; Asia Pacific Working Group on Colorectal Cancer. Increasing incidence of colorectal cancer in Asia: implications for screening. Lancet Oncol 2005; 6:871-6.

30. Teo EK, Fock KM. Hepatocellular Carcinoma: An Asian Perspective. Dig Dis 2001; 19:263-8.

31. McGlynn KA, London WT. Epidemiology and natural history of hepatocellular carcinoma. Best Pract Res Clin Gastroenterol 2005; 19:3-23.

32. Han KH, Ahn SH. How to predict HCC development in patients with chronic B-viral liver disease? Intervirology 2005; 48: 23-28.

33. Asim M, Sarma MP, Kar P. Etiological and molecular profile of hepatocellular cancer from India. Int J Cancer 2013; 133:437-45.

34. Kim SR, Kudo M, Hino O, Han KH, Chung YH, Lee HS; Organizing Committee of Japan-Korea Liver Symposium. Epidemiology of hepatocellular carcinoma in Japan and Korea. A review. Oncology 2008; 75:S13-6.

35. Park JW, Kim CM. Epidemiology of hepatocellular carcinoma in Korea. Korean J Hepatol 2005; 11: 303-10.

36. Pourhoseingholi MA, Fazeli Z, Zali MR, Alavian SM. Burden of hepatocellular carcinoma in Iran; Bayesian projection and trend analysis. Asian Pac J Cancer Prev 2010; 11:859-62.

37. Anand R. Aflatoxins, in: IARC monograph on the evaluation of carcinogenic risks to humans, vol. 82, in: Some Traditional Herbal Medicines Some Mycotoxins, Naphthalene and Styrene. New York: McGraw-Hill; 2002. P.171-300.

38. Chuang SC, La Vecchia C, Boiffetta P. Liver cancer: descriptive epidemiology and risk factors other than HBV and HCV infection. Cancer Lett 2009; 286:9-14.

39. Liu Y, Wu F. Global burden of aflatoxin-induced hepatocellular carcinoma: a risk assessment. Environ Health Perspect 2010; 118:818-24.

40. Cai L, Chongsuvivatwong V, Geater A. Changing pattern of premature mortality burden over 6 years of rapid growth of the economy in suburban south-west China: 1998-2003. Public Health 2008; 122:478-86.

41. Yang GH, Wang JF, Wan X, Wang LJ, Chen AP. Quantitative analysis of factors affected mortality trend in Chinese, 2002. Zhonghua Liu Xing Bing Xue Za Zhi 2005; 26:934-8.

42. Bae JM, Jung KW, Won YJ. Estimation of cancer deaths in Korea for the upcoming years. J Korean Med Sci 2002; 17:611-15.

43. Yoshimi I, Sobue T. Mortality trend of liver cancer in Japan: 1960–2000. Jpn J Clin Oncol 2003; 33:202-3.

44. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 2005; 55:74-108.

45. Polednak AP. Trends in survival for both histologic types of esophageal cancer in US surveillance, epidemiology and end results areas. Int J Cancer 2003; 105: 98-100.

46. Qureshi I, Shende M, Luketich JD. Surgical palliation for Barrett's esophagus cancer. Surg Oncol Clin N Am. 2009; 18:547-60.

47. Mosavi-Jarrah A, Mohagheghi MA. Epidemiology of esophageal cancer in the high-risk population of Iran. Asian Pac J Cancer Prev 2006; 7:375-80.

48. Chen ZH, Shao JL, Lin JR, Zhang X, Chen Q. Reproductive factors and oesophageal cancer in Chinese women: a case-control study. BMC Gastroenterol 2011; 9:11-49.

49. Ke L. Mortality and incidence trends from esophagus cancer in selected geographic areas of China circa 1970-90. Int J Cancer 2002; 102:271-74.

50. Qiu D, Kaneko S. Comparison of esophageal cancer mortality in five countries: France, Italy, Japan, UK and USA from the WHO mortality database (1960-2000). Jpn J Clin Oncol 2005; 35:564-67.

51. Pourhoseingholi MA, Fazeli Z, Ashtari S, Bavand-Pour FS. Mortality trends of gastrointestinal cancers in Iranian population. Gastroenterol Hepatol Bed Bench 2013; 6:S52-57.

52. Ryu JK, Hong SM, Karikari CA, Hruban RH, Goggins MG, Maitra A. Aberrant MicroRNA-155 expression is an early event in the multistep progression of pancreatic adenocarcinoma. Pancreatology 2010; 10:66-73.

53. Worldwide cancer mortality statistics. [cited 2002-06]. Available form: URL: http://www-depdb.iarc.fr/who/menu.htm

54. Katanoda K, Yako-Suketomo H. Comparison of time trends in pancreatic cancer mortality (1990-2006) between countries based on the WHO mortality database. Jpn J Clin Oncol 2010; 40:601-2.
55. Wang L, Yang GH, Lu XH, Huang ZJ, Li H. Pancreatic cancer mortality in China (1991-2000). World J Gastroenterol 2003; 9:1819-23.

56. Pourhoseingholi MA, Pourhoseingholi A, Vahedi M, Ashtari S, Safaee A, Moghimi-Dehkordi B, et al. Decreased trend of pancreatic cancer mortality in Iran. Asian Pac J Cancer Prev 2011; 12:153-55.

57. Taghavi A, Fazeli Z, Vahedi M, Baghestani AR, Zali MR, Pourhoseingholi MA. Pancreatic cancer mortality and misclassification–bayesian analysis. Asian Pac J Cancer Prev 2011; 12:2271-74.

58. Larsson SC, Permert J, Hakansson N, Naslund I, Bergkvist L, Wolk A. Overall obesity, abdominal adiposity, diabetes and cigarette smoking in relation to the risk of pancreatic cancer in two Swedish population-based cohorts. Br J Cancer 2005; 93:1310-15.

59. Ansary-Moghaddam A, Huxley R, Barzi F, Lawes C, Okubo T, Fang X, et al. The Effect of Modifiable Risk Factors on Pancreatic Cancer Mortality in Populations of the Asia-Pacific Region. Cancer Epidemiol Biomarkers Prev 2006; 15:2435-40.

60. Inoue M, Tajima K, Takezaki T, Hamajim N, Hirose K, Ito H, Tominaga S. Epidemiology of pancreatic cancer in Japan: a nested case-control study from the Hospital-based Epidemiologic Research Program at Aichi Cancer Center (HERPACC). Int J Epidemiol 2003; 32:257-62.

61. Lai EC, Lau WY. The continuing challenge of hepatic cancer in Asia. Surgeon 2005; 3:210-5.

62. IARC Unit of Descriptive Epidemiology: WHO cancer mortality databank. Cancer Mondial, 2001; Available from URL: www-dep.iarc.fr/ataava/globocan/who.htm.

63. Yang L. Incidence and mortality of gastric cancer in China. World J Gastroenterol 2006; 12:17-20.

64. World Health Organization (WHO): National cancer control programmes: policies and managerial guidelines. Second version. Geneva: World Health Organization, 2002.

65. Pourhoseingholi MA. Increased burden of colorectal cancer in Asia. World J Gastrointest Oncol 2012; 4:68-70.

66. Pourhoseingholi MA, Zali MR. Colorectal cancer screening: Time for action in Iran. World J Gastrointest Oncol 2012; 4:82-83.
کارگاه‌های آموزشی مرکز اطلاعات علمی

مقاله نویسی علوم انسانی

اصول تنظیم قراردادها

آموزش مهارت های کاربردی در تدوین و چاپ مقاله